OverviewSuggest Edit

Avacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. It operates through three segments: Analytical, Animal Health and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health segment provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited and others.
TypePublic
Founded2003
HQWetherby, GB
Websiteavacta.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Jul 2021)123(+4%)
Revenue (FY, 2018)£1.2 M(-3%)
Share Price (Sept 2021)£1.3(+18%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Avacta Group

Alastair Smith

Alastair Smith

Chief Executive Officer and Director
Tony Gardiner

Tony Gardiner

Chief Financial Officer and Director
Trevor Nicholls

Trevor Nicholls

Non Executive Director
Paul Fry

Paul Fry

Non Executive Director
Eliot Forster

Eliot Forster

Non Executive Chairman
Michael Vinegrad

Michael Vinegrad

Group Communications Director
Show more

Avacta Group Office Locations

Avacta Group has offices in Wetherby, London and Whittlesford
Wetherby, GB (HQ)
Unit 20, Ash Way, Thorp Arch Estate & Retail Park
London, GB
200 Aldersgate St, Barbican
Whittlesford, GB
LION WORKS, Station Rd W
Show all (3)

Avacta Group Financials and Metrics

Avacta Group Revenue

Avacta Group's revenue was reported to be £1.24 m in FY, 2018
GBP

Revenue (FY, 2018)

1.2m

Gross profit (FY, 2018)

837.1k

Gross profit margin (FY, 2018), %

67.8%

Net income (FY, 2018)

(7.8m)

EBIT (FY, 2018)

(9.2m)

Market capitalization (22-Sept-2021)

319.3m

Closing stock price (22-Sept-2021)

1.3

Cash (31-Jul-2018)

571.5k

EV

352.6m
Avacta Group's current market capitalization is £319.3 m.
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

8.7k29.8k171.5k866.8k1.3m1.2m

Revenue growth, %

475%405%

Cost of goods sold

4.0k10.5k77.0k451.1k422.5k398.4k

Gross profit

4.7k19.3k94.5k415.6k859.4k837.1k
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

32.8k298.3k113.4k40.0k23.7k385.9k246.4k96.3k115.9k571.5k

Accounts Receivable

2.4k5.8k12.0k61.1k45.3k81.3k157.6k

Inventories

173.4k274.8k215.4k72.7k69.3k

Current Assets

35.2k304.2k118.1k100.3k214.1k1.0m1.7m2.4m2.3m3.5m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(388.1k)(977.4k)(2.3m)(4.9m)(6.0m)(6.6m)

Income Taxes Paid

310.5k370.5k1.0m
GBPFY, 2009

Financial Leverage

-0.9 x
Show all financial metrics

Avacta Group Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Avacta Group Online and Social Media Presence

Embed Graph

Avacta Group News and Updates

Avacta Group Plc (AVCT) Market Clinical Trials Review, H2, 2017 Strategies 2017 by Analyzing the Performance of Various Competitors

WiseGuyReports published new report, titled “Avacta Group Plc (AVCT)” Posted via Industry Today. Follow us on Twitter @IndustryToday

Avacta Group Blogs

Interim Results for the Period Ended 30 June 2021 and Business Update

The post Interim Results for the Period Ended 30 June 2021 and Business Update appeared first on Avacta Life Sciences Limited.

Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

The post Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership appeared first on Avacta Life Sciences Limited.

Lateral Flow Assay Testing for COVID-19 – Tackling asymptomatic spread

The post Lateral Flow Assay Testing for COVID-19 – Tackling asymptomatic spread appeared first on Avacta Life Sciences Limited.

Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division

The post Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division appeared first on Avacta Life Sciences Limited.

Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division

The post Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division appeared first on Avacta Life Sciences Limited.

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial

The post Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial appeared first on Avacta Life Sciences Limited.
Show more

Avacta Group Frequently Asked Questions

  • When was Avacta Group founded?

    Avacta Group was founded in 2003.

  • Who are Avacta Group key executives?

    Avacta Group's key executives are Alastair Smith, Tony Gardiner and Trevor Nicholls.

  • How many employees does Avacta Group have?

    Avacta Group has 123 employees.

  • What is Avacta Group revenue?

    Latest Avacta Group annual revenue is £1.2 m.

  • What is Avacta Group revenue per employee?

    Latest Avacta Group revenue per employee is £10 k.

  • Who are Avacta Group competitors?

    Competitors of Avacta Group include Stemina Biomarker Discovery, NanoView Biosciences and Proteome Sciences.

  • Where is Avacta Group headquarters?

    Avacta Group headquarters is located at Unit 20, Ash Way, Thorp Arch Estate & Retail Park, Wetherby.

  • Where are Avacta Group offices?

    Avacta Group has offices in Wetherby, London and Whittlesford.

  • How many offices does Avacta Group have?

    Avacta Group has 3 offices.